Petar Seferovic

List of Publications by Year in descending order

91 papers	5,130 citations	159585 30 h-index	98798 67 g-index
91 all docs	91 docs citations	91 times ranked	5259 citing authors

#	Article	IF	Citations
1	Withdrawn as duplicate: Optimized Implementation of cardiac resynchronization therapy â€“ a call for action for referral and optimization of care. Europace, 2023, 25, .	1.7	2
2	Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovascular Research, 2023, 118, 3272-3287.	3.8	517
3	Multimodality imaging in patients with heart failure and preserved ejection fraction: an expert consensus document of the European Association of Cardiovascular Imaging. European Heart Journal Cardiovascular Imaging, 2022, 23, e34-e61.	1.2	140
4	Sodiumâ€“glucose coâ€transporter 2 inhibitors as an early, firstâ€line therapy in patients with heart failure and reduced ejection fraction. European Journal of Heart Failure, 2022, 24, 431-441.	7.1	67
5	Education and certification on heart failure of the <scp>H</scp>eart <scp>F</scp>ailure <scp>A</scp>ssociation of the <scp>E</scp>uropean <scp>S</scp>ociety of <scp>C</scp>ardiology. European Journal of Heart Failure, 2022, 24, 249-253.	7.1	6
6	A comprehensive characterization of acute heart failure with preserved versus mildly reduced versus reduced ejection fractionÂâ€“Âinsights from the <scp>ESCâ€HFA EORP</scp> Heart Failure Longâ€Term Registry. European Journal of Heart Failure, 2022, 24, 335-350.	7.1	49
7	European Society of Cardiology quality indicators for the care and outcomes of adults with heart failure. Developed by the Working Group for Heart Failure Quality Indicators in collaboration with the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2022, 24, 132-142.	7.1	30
8	European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1â€”epidemiology, pathophysiology, and diagnosis. Cardiovascular Research, 2022, 118, 1385-1412.	3.8	27
9	Data standards for heart failure: the European Unified Registries for Heart Care Evaluation and Randomized Trials (EuroHeart). European Heart Journal, 2022, 43, 2185-2195.	2.2	12
10	Cardiac remodellingÂâ€“ÂPart 1: From cells and tissues to circulating biomarkers. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2022, 24, 927-943.	7.1	29
11	Renal effects of guidelineâ€directed medical therapies in heart failure: a consensus document from the Heart Failure <scp>Association of the European Society of Cardiology</scp>. European Journal of Heart Failure, 2022, 24, 603-619.	7.1	57
12	Atrial disease and heart failure: the common soil hypothesis proposed by the Heart Failure Association of the European Society of Cardiology. European Heart Journal, 2022, 43, 863-867.	2.2	14
13	Cardiac remodellingÂâ€“ÂPart 2: Clinical, imaging and laboratory findings. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2022, 24, 944-958.	7.1	22
14	Headâ€toâ€head comparison between recommendations by the <scp>ESC</scp> and <scp>ACC</scp>/<scp>AHA</scp>/<scp>HFSA</scp> heart failure guidelines. European Journal of Heart Failure, 2022, 24, 916-926.	7.1	18
15	Does endâ€organ dysfunction precede or follow cardiogenic shock in acute decompensated heart failure? The twoâ€faced Janus. Reply. European Journal of Heart Failure, 2021, 23, 197-198.	7.1	1
16	Myocarditis and inflammatory cardiomyopathy: current evidence and future directions. Nature Reviews Cardiology, 2021, 18, 169-193.	13.7	589
17	Selfâ€care of heart failure patients: practical management recommendations from the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2021, 23, 157-174.	7.1	181
18	OUP accepted manuscript. European Journal of Preventive Cardiology, 2021, , .	1.8	0

#	Article	IF	Citations
19	Pathophysiological Basis for Nutraceutical Supplementation in Heart Failure: A Comprehensive Review. Nutrients, 2021, 13, 257.	4.1	24
20	The <scp>Heart Failure Association Atlas</scp>: <scp>Heart Failure Epidemiology and Management Statistics</scp> 2019. European Journal of Heart Failure, 2021, 23, 906-914.	7.1	130
21	Optimized implementation of cardiac resynchronization therapy: a call for action for referral and optimization of care. Europace, 2021, 23, 1324-1342.	1.7	18
22	Heart Failure Association of the ESC, Heart Failure Society of America and Japanese Heart Failure Society Position statement on endomyocardial biopsy. European Journal of Heart Failure, 2021, 23, 854-871.	7.1	105
23	Heart Failure Association, Heart Failure Society of America, and Japanese Heart Failure Society Position Statement on Endomyocardial Biopsy. Journal of Cardiac Failure, 2021, 27, 727-743.	1.7	29
24	Cardiac, renal, and metabolic effects of sodiumâ€“glucose coâ€transporter 2 inhibitors: a position paper from the European Society of Cardiology adâ€hoc task force on sodiumâ€“glucose coâ€transporter 2 inhibitors. European Journal of Heart Failure, 2021, 23, 1260-1275.	7.1	36
25	The â€˜Peptide for Lifeâ€™ Initiative: a call for action to provide equal access to the use of natriuretic peptides in the diagnosis of acute heart failure across <scp>Europe</scp>. European Journal of Heart Failure, 2021, 23, 1432-1436.	7.1	10
26	Guidance on the management of left ventricular assist device <scp>(LVAD)</scp> supported patients for the nonâ€<scp>LVAD</scp> specialist healthcare provider: executive summary. European Journal of Heart Failure, 2021, 23, 1597-1609.	7.1	20
27	Heart Failure Association of the European Society of Cardiology position paper on the management of left ventricular assist deviceâ€supported patients for the nonâ€left ventricular assist device specialist healthcare provider: Part 2: at the emergency department. ESC Heart Failure, 2021, 8, 4409-4424.	3.1	7
28	Circulating heart failure biomarkers beyond natriuretic peptides: review from the Biomarker Study Group of the Heart Failure Association (<scp>HFA</scp>), European Society of Cardiology (<scp>ESC</scp>). European Journal of Heart Failure, 2021, 23, 1610-1632.	7.1	69
29	Integration of imaging and circulating biomarkers in heart failure: a consensus document by the Biomarkers and Imaging Study Groups of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2021, 23, 1577-1596.	7.1	23
30	HFA of the ESC Position paper on the management of LVAD supported patients for the non LVAD specialist healthcare provider Part 1: Introduction and at the nonâ€hospital settings in the community. ESC Heart Failure, 2021, 8, 4394-4408.	3.1	5
31	HFA of the ESC position paper on the management of LVADâ€supported patients for the nonâ€LVAD specialist healthcare provider Part 3: at the hospital and discharge. ESC Heart Failure, 2021, 8, 4425-4443.	3.1	10
32	Changes in the SARS-CoV-2 cellular receptor ACE2 levels in cardiovascular patients: a potential biomarker for the stratification of COVID-19 patients. GeroScience, 2021, 43, 2289-2304.	4.6	13
33	<scp>COVID</scp>â€19 vaccination in patients with heart failure: a position paper of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2021, 23, 1806-1818.	7.1	32
34	ESC/HFA Quality of Care Centres: the ultimate frontier in unifying heart failure management. European Heart Journal, 2021, 43, 11-13.	2.2	5
35	An ounce of prevention is worth a pound of cure: drugs and devices to prevent sudden cardiac death in heart failure. European Journal of Preventive Cardiology, 2021, 28, 107-109.	1.8	0
36	Navigating between Scylla and Charybdis: challenges and strategies for implementing guidelineâ€directed medical therapy in heart failure with reduced ejection fraction. European Journal of Heart Failure, 2021, 23, 1999-2007.	7.1	22

#	Article	IF	Citations
37	Pulmonary hypertension and right ventricular remodeling in HFpEF and HFrEF. Heart Failure Reviews, 2020, 25, 85-91.	3.9	12
38	Sexâ€•and ageâ€•related differences in the management and outcomes of chronic heart failure: an analysis of patients from the ESC HFA EORP Heart Failure Longâ€•Term Registry. European Journal of Heart Failure, 2020, 22, 92-102.	7.1	81
39	Imaging in patients with suspected acute heart failure: timeline approach position statement on behalf of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2020, 22, 181-195.	7.1	47
40	Type 2 diabetes increases the longâ€•term risk of heart failure and mortality in patients with atrial fibrillation. European Journal of Heart Failure, 2020, 22, 113-125.	7.1	23
41	<scp>Heart Failure Association</scp> of the <scp>European Society of Cardiology</scp> update on sodiumâ€“glucose coâ€•transporter 2 inhibitors in heart failure. European Journal of Heart Failure, 2020, 22, 1984-1986.	7.1	66
42	Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the <scp>Cardioâ€Oncology Study Group</scp> of the <scp>Heart Failure Association</scp> and the <scp>Cardioâ€Oncology Council of the European Society of Cardiology</scp>. European Journal of Heart Failure, 2020, 22, 1966-1983.	7.1	184
43	Optimized implementation of cardiac resynchronization therapy: a call for action for referral and optimization of care. European Journal of Heart Failure, 2020, 22, 2349-2369.	7.1	101
44	In search of a â€˜safety zoneâ€™ for glycaemic control: association between <scp>glycosylated haemoglobin</scp> levels and outcomes in patients with type 2 diabetes and cardiovascular disease. European Journal of Heart Failure, 2020, 22, 2035-2037.	7.1	2
45	Nonâ€•insulin antihyperglycaemic drugs and heart failure: an overview of current evidence from randomized controlled trials. ESC Heart Failure, 2020, 7, 3438-3451.	3.1	13
46	Epidemiology, pathophysiology and contemporary management of cardiogenic shockÂâ€“Âa position statement from the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2020, 22, 1315-1341.	7.1	244
47	Heart Failure Association of the European Society of Cardiology Quality of Care Centres Programme: design and accreditation document. European Journal of Heart Failure, 2020, 22, 763-774.	7.1	24
48	Practice makes perfect: improved longâ€•term survival in nonâ€•ischaemic dilated cardiomyopathy with contemporary treatment. European Journal of Heart Failure, 2020, 22, 1122-1124.	7.1	0
49	Is heart failure misdiagnosed in hospitalized patients with preserved ejection fraction? From the European Society of Cardiology â€•Heart Failure Association EURObservational Research Programme Heart Failure Longâ€•Term Registry. ESC Heart Failure, 2020, 7, 2098-2112.	3.1	23
50	Sodiumâ€“glucose coâ€•transporter 2 inhibitors in heart failure: beyond glycaemic control. A position paper of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2020, 22, 1495-1503.	7.1	100
51	The Heart Failure Association Atlas: rationale, objectives, and methods. European Journal of Heart Failure, 2020, 22, 638-645.	7.1	23
52	A putative placebo analysis of the effects of sacubitril/valsartan in heart failure across the full range of ejection fraction. European Heart Journal, 2020, 41, 2356-2362.	2.2	38
53	Crouching tiger, hidden dragon: insulin resistance and the risk of atrial fibrillation. European Journal of Preventive Cardiology, 2020, 27, 1931-1933.	1.8	5
54	Oxidative stress and inflammation in heart failure: The best is yet to come. European Journal of Preventive Cardiology, 2020, 27, 490-493.	1.8	10

#	Article	IF	Citations
55	Glutathione Transferase P1 Polymorphism Might Be a Risk Determinant in Heart Failure. Disease Markers, 2019, 2019, 1-11.	1.3	20
56	Cutting the Gordian knot of left ventricular diastolic dysfunction: Role of opportunistic screening models. European Journal of Preventive Cardiology, 2019, 26, 1666-1669.	1.8	0
57	Regional differences in exercise training implementation in heart failure: findings from the Exercise Training in Heart Failure (ExTraHF) survey. European Journal of Heart Failure, 2019, 21, 1142-1148.	7.1	14
58	Heart Failure Association of the European Society ofÂCardiology position paper on frailty in patients with heart failure. European Journal of Heart Failure, 2019, 21, 1299-1305.	7.1	144
59	The eyes are the mirror of the heart: role of retinal microvascular abnormalities in predicting longâ€term risk of heart failure. European Journal of Heart Failure, 2019, 21, 1216-1218.	7.1	0
60	Is left atrium the best kept secret of the heart? Left atrial dilatation and cardiovascular outcomes. Heart, 2019, 105, 1848-1849.	2.9	7
61	Sacubitril/valsartan eligibility and outcomes in the ESCâ€EORPâ€HFA Heart Failure Longâ€Term Registry: bridging between European Medicines Agency/Food and Drug Administration label, the PARADIGMâ€HF trial, ESC guidelines, and real world. European Journal of Heart Failure, 2019, 21, 1383-1397.	7.1	35
62	Acute heart failure congestion and perfusion statusÂâ€“Âimpact of the clinical classification on inâ€hospital and longâ€term outcomes; insights from the ESCâ€EORPâ€HFA Heart Failure Longâ€Term Registry. European Journal of Heart Failure, 2019, 21, 1338-1352.	7.1	170
63	Age old problem: heart failure treatment in elderly. European Journal of Preventive Cardiology, 2019, 26, 1396-1398.	1.8	3
64	Heart failure in cardiomyopathies: a position paper from the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2019, 21, 553-576.	7.1	224
65	Association between heart rate variability and haemodynamic response to exercise in chronic heart failure. Scandinavian Cardiovascular Journal, 2019, 53, 77-82.	1.2	4
66	The role of ventriculararâ€“arterial coupling in cardiac disease and heart failure: assessment, clinical implications and therapeutic interventions. A consensus document of the European Society of Cardiology Working Group on Aorta & Peripheral Vascular Diseases, European Association of Cardiovascular Imaging, and Heart Failure Association. European Journal of Heart Failure, 2019, 21, 402-424.	7.1	202
67	Vaccination in Patients With Heart Disease. How Long Should We Wait? Response. Revista Espanola De Cardiologia (English Ed), 2019, 72, 516.	0.6	0
68	Heart failure with preserved ejection fraction in Asia: the far side of the moon?. European Journal of Heart Failure, 2019, 21, 37-39.	7.1	6
69	Lipoprotein apheresis and proprotein convertase subtilisin/kexin type 9 inhibitors: Do we have a vanquishing new strategy?. European Journal of Preventive Cardiology, 2019, 26, 739-742.	1.8	3
70	Long-term mortality is increased in patients with undetected prediabetes and type-2 diabetes hospitalized for worsening heart failure and reduced ejection fraction. European Journal of Preventive Cardiology, 2019, 26, 72-82.	1.8	27
71	Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2018, 20, 853-872.	7.1	434
72	Vaccination in Heart Failure: An Approach to Improve Outcomes. Revista Espanola De Cardiologia (English Ed), 2018, 71, 697-699.	0.6	2

#	Article	IF	Citations
73	Heart and brain interaction in patients with heart failure: overview and proposal for a taxonomy. A position paper from the Study Group on Heart and Brain Interaction of the Heart Failure Association. European Journal of Heart Failure, 2018, 20, 199-215.	7.1	128
74	Longâ€term safety of intravenous cardiovascular agents in acute heart failure: results from the European Society of Cardiology Heart Failure Longâ€Term Registry. European Journal of Heart Failure, 2018, 20, 332-341.	7.1	69
75	Innovative imaging methods in heart failure: a shifting paradigm in cardiac assessment. Position statement on behalf of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2018, 20, 1615-1633.	7.1	74
76	A step forward in resolving an old issue: treatment of heart failure with preserved ejection fraction and renal dysfunction?. European Journal of Preventive Cardiology, 2018, 25, 1263-1267.	1.8	2
77	Adipokine profile as a novel screening method for cardiometabolic disease: Help or hindrance?. European Journal of Preventive Cardiology, 2018, 25, 1543-1547.	1.8	1
78	Association of metabolic syndrome with non-thromboembolic adverse cardiac outcomes in patients with atrial fibrillation. European Heart Journal, 2018, 39, 4030-4039.	2.2	19
79	Oxidized Low-Density Lipoprotein Predicts the Development of Renal Dysfunction in Atrial Fibrillation. CardioRenal Medicine, 2017, 7, 31-41.	1.9	8
80	N-terminal pro-brain natriuretic peptide is related with coronary flow velocity reserve and diastolic dysfunction in patients with asymmetric hypertrophic cardiomyopathy. Journal of Cardiology, 2017, 70, 323-328.	1.9	25
81	Percutaneous Therapy in Pericardial Diseases. Cardiology Clinics, 2017, 35, 567-588.	2.2	20
82	Adverse cardiovascular outcomes in atrial fibrillation: Validation of the new 2MACE risk score. International Journal of Cardiology, 2017, 249, 191-197.	1.7	22
83	Patientsâ€™ knowledge and perspectives on vitamin K antagonists for stroke prevention in atrial fibrillation: implications for treatment quality. Anatolian Journal of Cardiology, 2017, 18, 239-240.	0.9	1
84	Pharmacokinetics and pharmacodynamics of cardiovascular drugs in chronic heart failure. International Journal of Cardiology, 2016, 224, 191-198.	1.7	37
85	<scp>ExtraHF</scp> survey: the first European survey on implementation of exercise training in heart failure patients. European Journal of Heart Failure, 2015, 17, 631-638.	7.1	69
86	Typical chest pain and precordial leads ST-elevation in patients with pacemakers - are we always looking at an acute myocardial infarction?. Vojnosanitetski Pregled, 2015, 72, 837-840.	0.2	0
87	Mitral valve endocarditis caused by Pseudomonas aeruginosa: a case report. Journal of Infection in Developing Countries, 2014, 8, 676-679.	1.2	5
88	Endothelial (Dys)Function in Lone Atrial Fibrillation. Current Pharmaceutical Design, 2014, 21, 622-645.	1.9	20
89	Impaired endothelial function in lone atrial fibrillation. Vojnosanitetski Pregled, 2013, 70, 908-914.	0.2	18
90	Mitral valve endocarditis during brucellosis relapse. Vojnosanitetski Pregled, 2012, 69, 725-729.	0.2	1

#	Article	IF	Citations
91	Medical Treatment of Heart Failure with Reduced Ejection Fraction in the Elderly. Cardiac Failure Review, 0, 8, .	3.0	1